Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Paolo Ghia, MD, PhD, full professor, Medical Oncology, group leader, B-cell Neoplasia Unit, head, Strategic Research Program on CLL, Università Vita Salute San Raffaele, deputy director, Division of Experimental Oncology, San Raffaele Scientific Institute, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial (NCT03336333) investigating zanubrutinib (Brukinsa) vs bendamustine (Bendeka) plus rituximab (Rituxan; BR) in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without 17p deletions.